|
|
Post by sayhey24 on Jul 28, 2022 11:57:05 GMT -5
|
|
|
|
Post by centralcoastinvestor on Jul 28, 2022 17:18:38 GMT -5
Another great interview. Mike is doing a great job of getting out there to do interviews. My biggest takeaway: Mike has diabetes. He has a family history of it. Mike is deeply and truly committed to diabetes treatment. He will make Afrezza successful because he believes this is the only new diabetes treatment that will come along for the next 10 to 20 years.
|
|
|
|
Post by helmut8056 on Jul 31, 2022 12:22:37 GMT -5
Another great interview. Mike is doing a great job of getting out there to do interviews. My biggest takeaway: Mike has diabetes. He has a family history of it. Mike is deeply and truly committed to diabetes treatment. He will make Afrezza successful because he believes this is the only new diabetes treatment that will come along for the next 10 to 20 years. So why does he keep ignoring professionals who want to assist him like Bill? |
|
|
|
Post by sayhey24 on Aug 1, 2022 6:38:21 GMT -5
I think Mike has had lots of "experts" telling him all kinds of things. He some times calls them "thought leaders". In the podcast when asked why have things taken so long he mentions that most of these experts who do the studies and influence have not been involved for years and in those years GLP1s, SGLT2s have taken the spot light or better said in my words - BP has been paying these guys big money. Money talks and if a guy like Ralph DeFronzo is getting paid big bucks to find good things on GLP1s I bet he will be able to.
Then you got a guy like Bill. He is not a diabetes "thought leader". He does not have all kinds of letters after his name. He is a guy who knew Al Mann and believed what Al was saying. He is a guy saying "afrezza first, afrezza always" and the "thought leaders" are saying slow down. At the same time Mike is getting feedback that afrezza doesn't always work and has not figured out these people are under dosing. Mike also has no money and surely can't give Bill any. Just getting VDex all the free samples they want is costly.
So that was yesterday. Today Mike has some money. We know the 2 big users issues are under dosing and coughing. We know Mounjaro wants to be the #1 T2 drug. We know the "thought leaders" control recommendations to change the SoC AND, we know Bill is saying afrezza can provide relief from GERDS.
For Bill the next step is easy - put a small informal pilot study together for GERDS. If that pans out I am sure he would have Mikes ear to do a formal pilot study and assuming success a larger study. The way I see it, the ball is now in Bill's court.
|
|
|
|
Post by sportsrancho on Aug 1, 2022 22:25:54 GMT -5
YES❣️
|
|
